Premium
Incorporation of TIP (paclitaxel, ifosfamide, cisplatin) into first‐line therapy for intermediate to poor risk testicular germ cell tumors with unfavorable marker decline after initial two cycles chemotherapy: A report of three cases
Author(s) -
Ishioka JunIchiro,
Kageyama Yukio,
Ichiyanagi Nobutaka,
Fukuda Hiroshi,
Higashi Yotsuo
Publication year - 2007
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2007.01755.x
Subject(s) - medicine , bleomycin , etoposide , ifosfamide , vinblastine , germ cell tumors , cisplatin , testicular cancer , paclitaxel , oncology , chemotherapy , germ cell , testicular germ cell tumor , carboplatin , urology , biochemistry , chemistry , gene
Three patients of advanced‐non‐seminomatous germ cell tumors (International Germ Cell Cancer Collaborative Group classification: poor risk, 2; intermediate, 1) without evidence of a second primary germ cell tumor were treated. The patients received two cycles of standard BEP (bleomycin, etopside, cisplatin) or VIP/VB (etoposide, ifosphamide, cisplatin/vinblastine, bleomycin) therapy first. All patients in this trial showed unfavorable marker response to these therapies and received four cycles of TIP subsequently. A complete remission was observed in all patients. No patient experienced life‐threatening toxicity. During the 34‐month observation period, all patients were alive without progression.